Detalhe da pesquisa
1.
Real-world relationship of early end points to survival end points in patients with resectable non-small-cell lung cancer.
Future Oncol
; 19(26): 1785-1800, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-37665271
2.
Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018.
BMC Pulm Med
; 23(1): 16, 2023 Jan 13.
Artigo
Inglês
| MEDLINE | ID: mdl-36639770
3.
Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis.
BMC Cancer
; 22(1): 255, 2022 Mar 10.
Artigo
Inglês
| MEDLINE | ID: mdl-35264135
4.
Adverse events and clinical outcomes in patients treated with PD-(L)1 blockade for advanced non-small-cell lung cancer.
Future Oncol
; 18(40): 4509-4523, 2022 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-36942686
5.
Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study.
Future Oncol
; 18(2): 205-214, 2022 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-34784783
6.
Measuring the Value Healthy Individuals Place on Generous Insurance Coverage of Severe Diseases: A Stated Preference Survey of Adults Diagnosed With and Without Lung Cancer.
Value Health
; 24(6): 855-861, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-34119084
7.
Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting.
Future Oncol
; 17(19): 2439-2448, 2021 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-33769073
8.
Small cell lung cancer treatment and survival in Portugal: A retrospective analysis from the I-O Optimise initiative.
Eur J Cancer Care (Engl)
; 30(6): e13496, 2021 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-34288191
9.
Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
BMC Pulm Med
; 20(1): 240, 2020 Sep 10.
Artigo
Inglês
| MEDLINE | ID: mdl-32912174
10.
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Lancet Oncol
; 20(10): 1395-1408, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-31422028
11.
I-O Optimise: a novel multinational real-world research platform in thoracic malignancies.
Future Oncol
; 15(14): 1551-1563, 2019 May.
Artigo
Inglês
| MEDLINE | ID: mdl-30852916
12.
The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions.
Popul Health Metr
; 16(1): 17, 2018 11 26.
Artigo
Inglês
| MEDLINE | ID: mdl-30477516
13.
Caring for relatives with lung cancer in Europe: an evaluation of caregivers' experience.
Qual Life Res
; 24(12): 2843-52, 2015 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-26068731
14.
Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer.
Pharmacoeconomics
; 42(1): 109-116, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-37707719
15.
Pathological response in resectable non-small cell lung cancer: a systematic literature review and meta-analysis.
JNCI Cancer Spectr
; 8(3)2024 Apr 30.
Artigo
Inglês
| MEDLINE | ID: mdl-38521542
16.
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
J Immunother Cancer
; 12(2)2024 Feb 12.
Artigo
Inglês
| MEDLINE | ID: mdl-38346853
17.
General population reference values for the Functional Assessment of Cancer Therapy-Lung and PROMIS-29.
Cancer Med
; 12(11): 12765-12776, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37148552
18.
Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China.
Pharmacoecon Open
; 7(2): 273-284, 2023 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-36897427
19.
Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis.
Lung Cancer
; 177: 11-20, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36669321
20.
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes.
Eur J Cancer
; 183: 174-187, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36871487